6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]
Published on
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
______________________________________________
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES
EXCHANGE ACT OF 1934
For the
month of December, 2009
Commission
File Number ________________
Novogen
Limited
(Translation
of registrant’s name into English)
140 Wicks
Road, North Ryde, NSW, Australia
(Address
of principal executive office)
___________________________________
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form 20-F
x Form 40-F o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(l): o
Note:
Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
6-K if submitted solely to provide an attached annual report to security
holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule lO1(b)(7): o
Note:
Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form 6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant’s security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes o No x
If “Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly
authorized.
Novogen
Limited
(Registrant)
/s/ Ron
Erratt
Ronald
Lea Erratt
Company
Secretary
Date
1 December, 2009
ASX
& MEDIA RELEASE
1
DECEMBER, 2009
ANNOUNCEMENT
TO THE STOCK EXCHANGE
Novogen
Limited advises that CEO and Managing Director Christopher Naughton will cease
his employment with the Company from today.
Mr
Naughton’s position as CEO of the US listed oncology subsidiary company Marshall
Edwards, Inc will terminate from today and a world-wide search for a replacement
is being initiated.
The
Company’s CFO, David Seaton, has been appointed acting CEO of the Group and he
will act in that capacity until a new CEO for Marshall Edwards has been
appointed. Following that, a permanent CEO will be appointed at
Novogen Limited.
“A
world-wide search for a new CEO of Marshall Edwards with drug development and
clinical oncology experience together with a track record of fund raising in the
US capital markets is being initiated”, said Philip Johnston, Chairman of the
Board, Novogen Limited.
“We are
all grateful for the contribution Mr Naughton has made to the Group over the
past 13 years and wish him well in his future endeavours. Over the
past few years, the focus of the Group and its principal subsidiary, Marshall
Edwards, has moved towards oncology drug discovery and
development. Due to the high priority of current and future clinical
programs, the Board considers the new appointment of a CEO dedicated to Marshall
Edwards is required to implement this
strategy”.